[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal]

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(9 Pt 2):113-22.
[Article in Russian]


The results of using ronbetal, the Russian biosimilar of interferon-beta 1b, in the treatment of multiple sclerosis (MS) are presented. The study included outpatients followed up from February 2008 to March 2012. All patients were assessed neurologically with additional evaluation using the EDSS; a number of exacerbations and their outcomes, disease progression, tolerability of the drug were recorded. No significant differences in the efficacy of ronbetal and betaferon were found. The frequency of exacerbations and MS progression were comparable for both drugs. The same was with the tolerability, with the exception of higher frequency of the flu-like syndrome at the beginning of treatment with ronbetal. A single-step substitution of betaferon for ronbetal often caused the discontinuation of treatment by patients because they were not fully informed about the new drug, need to use a new dose titration scheme and were anxious about side-effects.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Adult
  • Biological Products / therapeutic use*
  • Drug Substitution
  • Drugs, Generic / therapeutic use*
  • Female
  • Humans
  • Interferon beta-1b
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Russia
  • Treatment Outcome


  • Biological Products
  • Drugs, Generic
  • Interferon beta-1b
  • Interferon-beta